Alkem Laboratories' Q1 FY 2026-27 Quarterly Results

Result Summary

• Alkem Laboratories Ltd reported a 2.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 11.0%.
• Its expenses for the quarter were down by 3.8% QoQ and up 13.5% YoY.
• The net profit increased 107.5% QoQ and decreased 22.0% YoY.
• The earnings per share (EPS) of Alkem Laboratories Ltd stood at 43.49 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

## Company Overview
Alkem Laboratories Ltd is a prominent pharmaceutical company in India, known for its extensive range of products, including branded generics, active pharmaceutical ingredients, and nutraceuticals. It operates primarily in the pharmaceutical industry, focusing on the development, manufacture, and sale of pharmaceutical products. Alkem Laboratories has a strong presence not only in India but also in international markets, contributing to its diversified revenue streams. The company is recognized for its robust research and development capabilities, which support its pipeline of products catering to various therapeutic segments. Recent developments for the company are not available in the current dataset.

## Revenue
During the first quarter of FY27, Alkem Laboratories Ltd reported total income of ₹3892.90 crores. This reflects a quarter-over-quarter (QoQ) increase of 2.4% compared to ₹3803.39 crores in Q4FY26. On a year-over-year (YoY) basis, total income increased by 11.0% from ₹3507.63 crores in Q1FY26. The steady increase in revenue highlights the company's capacity to generate higher sales compared to both the previous quarter and the same quarter last year. The growth trajectory in revenue could potentially be attributed to the company's strong market position and product offerings, although specific market dynamics are not detailed in the available data.

## Profitability
Alkem Laboratories Ltd's profit before tax (PBT) for Q1FY27 was ₹771.99 crores, showing a significant QoQ growth of 82.6% from ₹422.85 crores in Q4FY26, and a marginal YoY increase of 0.1% from ₹771.01 crores in Q1FY26. The company's tax expense for the quarter was ₹250.50 crores, which increased by 46.3% QoQ and 143.9% YoY. Despite a substantial rise in tax expenses, the profit after tax (PAT) was ₹520.98 crores, more than double the previous quarter's PAT of ₹251.11 crores, reflecting a 107.5% increase QoQ. However, this was a decrease of 22.0% YoY from ₹667.91 crores in Q1FY26. The earnings per share (EPS) also followed a similar trend, standing at ₹43.49 for Q1FY27, representing a 120.0% QoQ increase and a 21.7% YoY decrease.

## Operating Metrics
Total expenses for Alkem Laboratories Ltd in Q1FY27 were ₹3120.91 crores, which is a decrease of 3.8% QoQ from ₹3245.57 crores in Q4FY26. However, expenses increased by 13.5% YoY from ₹2749.55 crores in Q1FY26. This reduction in expenses QoQ coupled with the increase in revenue contributed to the improvement in profitability metrics for the quarter. The notable rise in expenses YoY suggests an increase in operational activities or changes in cost structures over the year. The financial data suggests that the company has managed its operational costs effectively in the short term, as evidenced by the QoQ decrease in total expenses.